Second-generation immunomodulatory drugs in leptomeningeal myeloma

Leuk Lymphoma. 2019 Feb;60(2):550-552. doi: 10.1080/10428194.2018.1492125. Epub 2018 Jul 22.

Authors

Jan-Paul Bohn¹, Wolfgang Willenbacher^{1

2}, Ines Peschel³, Herbert Oberacher⁴, Michael Steurer¹

Affiliations

¹ a Department of Internal Medicine V , Medical University of Innsbruck , Innsbruck , Austria.
² b Oncotyrol , Center for Personalized Cancer Medicine , Innsbruck , Austria.
³ c Central Institute for Medical and Chemical Laboratory Diagnostics , Medical University Innsbruck , Innsbruck , Austria.
⁴ d Institute of Legal Medicine and Core Facility Metabolomics , Medical University of Innsbruck , Innsbruck , Austria.

PMID: 30032690
DOI: 10.1080/10428194.2018.1492125

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Lenalidomide / administration & dosage
Male
Meningeal Neoplasms / diagnosis
Meningeal Neoplasms / drug therapy*
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Thalidomide / administration & dosage
Thalidomide / therapeutic use
Treatment Outcome

Substances

Immunologic Factors
Thalidomide
Lenalidomide